Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.61 |
| ▸ | MMP3 | P08254 | 12/20 | 0.61 |
| ▸ | MMP7 | P09237 | 7/20 | 0.61 |
| ▸ | MMP2 | P08253 | 13/20 | 0.54 |
| ▸ | MMP9 | P14780 | 9/20 | 0.54 |
| ▸ | MMP8 | P22894 | 6/20 | 0.54 |
| ▸ | MMP13 | P45452 | 4/20 | 0.54 |
| ▸ | MMP14 | P50281 | 3/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 2/20 | 0.45 |
| ▸ | FCER2 | P06734 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7451414 | 0.89 | MMP1 (0.71) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7374287 | 0.79 | MMP1 (0.58) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7763578 | 0.79 | MMP1 (0.58) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7762136 | 0.76 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7758581 | 0.76 | MMP3 (0.61) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL6418504 | 0.74 | MMP1 (0.44) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7050036 | 0.74 | MMP1 (0.44) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7761307 | 0.73 | MMP1 (0.46) | MMP1MMP3MMP7MMP2MMP9 | |
| Ro-319790 SCHEMBL31060724 | 0.72 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| Ro-319790 SCHEMBL5494052 | 0.72 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |